DDInter1666 DDInter53
In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently facilitates relief in pulmonary arterial hypertension and the increased flow of blood into the spongy erectile tissue of the penis that consequently allows it to grow in size and become erect and rigid [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Interestingly enough, it is precisely via this mechanism why sildenafil was at first researched as a potential treatment
Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. There are several isoform-specific PI3K inhibitors that are under clinical development or currently approved, such as [idelalisib] used for chronic lymphocytic leukemia (CLL). Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with [fulvestrant] for postmenopausal women and male patients. To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests. Alpelisib is marketed under the trade name Piqray and is available as oral tablets. Studies evaluating the therapeutic effectiveness of alpelisib in other cancers, such as ovarian cancer and colorectal cancer , are under ongoing investigations. Alpelisib was granted FDA approval on 24 May 2019. In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy.
Sildenafil {u} (Compound) resembles {v} (Compound) Vardenafil
Vardenafil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Sildenafil {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Lurasidone
Lurasidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Sildenafil {u} (Compound) resembles {v} (Compound) Vardenafil
Vardenafil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canagliflozin
Canagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Sildenafil {u} (Compound) causes {v} (Side Effect) Anxiety
Anxiety {u} (Side Effect) is caused by {v} (Compound) Lurasidone
Lurasidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Sildenafil {u} (Compound) resembles {v} (Compound) Vardenafil
Vardenafil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Sildenafil {u} (Compound) resembles {v} (Compound) Vardenafil
Vardenafil {u} may lead to a major life threatening interaction when taken with {v} Cobicistat
Cobicistat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Sildenafil {u} (Compound) resembles {v} (Compound) Vardenafil
Vardenafil {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Ivosidenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Sildenafil {u} (Compound) resembles {v} (Compound) Vardenafil
Vardenafil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Rucaparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Sildenafil {u} (Compound) causes {v} (Side Effect) Atrioventricular block
Atrioventricular block {u} (Side Effect) is caused by {v} (Compound) Carbamazepine
Carbamazepine {u} may lead to a major life threatening interaction when taken with {v} Alpelisib
Sildenafil {u} (Compound) resembles {v} (Compound) Vardenafil
Vardenafil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lumacaftor
Lumacaftor {u} may lead to a major life threatening interaction when taken with {v} Alpelisib
Sildenafil (Compound) resembles Vardenafil (Compound) and Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Sildenafil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lurasidone (Compound) and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Sildenafil (Compound) resembles Vardenafil (Compound) and Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Sildenafil (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Lurasidone (Compound) and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Sildenafil (Compound) resembles Vardenafil (Compound) and Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Sildenafil (Compound) resembles Vardenafil (Compound) and Vardenafil may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Sildenafil (Compound) resembles Vardenafil (Compound) and Vardenafil may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Sildenafil (Compound) resembles Vardenafil (Compound) and Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Sildenafil (Compound) causes Atrioventricular block (Side Effect) and Atrioventricular block (Side Effect) is caused by Carbamazepine (Compound) and Carbamazepine may lead to a major life threatening interaction when taken with Alpelisib
Sildenafil (Compound) resembles Vardenafil (Compound) and Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor and Lumacaftor may lead to a major life threatening interaction when taken with Alpelisib